Allergy Therapeutics' Worthing Facility Receives Certificate of GMP Compliance - - BioPharm International

ADVERTISEMENT

Allergy Therapeutics' Worthing Facility Receives Certificate of GMP Compliance


Allergy Therapeutics, a pharmaceutical company specialized in allergy vaccination, announced that its Worthing facility has received its Certificate of GMP Compliance following recent inspection by the MHRA.

During the past seven years, more than £10 million has been invested in the upgrade of this injectables facility. The facility has the capacity to further increase output and operating efficiencies, with more than 210,000 allergy vaccines and diagnostic tests manufactured at this site each year and over 95% of sales made overseas. In the past 12 months, products have been supplied to new markets including the Baltic States and New Zealand.

Allergy Therapeutics employs around 200 people in Worthing and is proud of it trading heritage, spanning nearly 80 years.

Source: Allergy Therapeutics

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

J&J Speeds Ebola Vaccine Development and Expands Production
October 24, 2014
Despite AbbVie Snub, Shire Says it Will Double Sales by 2020
October 24, 2014
Manufacturing Challenges of mAb Production: CHO or Plant Cells?
October 24, 2014
Celgene and Sutro Partner on ADC Development
October 24, 2014
GSK Accelerates Ebola Vaccine Development
October 24, 2014
Author Guidelines

Click here